BAI, A novel cyclin-dependent kinase inhibitor induces apoptosis in A549 cells through activation of caspases and inactivation of Akt

Journal of Cellular Biochemistry

Volumn 114, Issue 2, 2013, Pages 282-293

  Kim, Shin ^a   Lee, Jinho ^a   Jang, Byeong Churl ^a   Kwon, Taeg Kyu ^a   Park, Jong Wook ^a  

^a Keimyung University   (South Korea)

Author keywords

Akt; Apoptosis; Bai; Caspase

Indexed keywords

2 (1,1' BIPHENYL) 4 YL N [5 (1,1 DIOXO 1LAMBDA6 ISOTHIAZOLIDIN 2 YL) 1H INDAZOL 3 YL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CASPASE; CYCLIN DEPENDENT KINASE INHIBITOR; INDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; PROTEIN MCL 1; ROSCOVITINE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CELL STRAIN HCT116; CELL VIABILITY; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TRANSIENT TRANSFECTION;

ACETAMIDES; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDAZOLES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; THIAZOLES; THIAZOLIDINES;

EID: 84872714211     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24314     Document Type: Article

References (41)

1. Ahmad N, Feyes DK, Nieminen AL, Agarwal R, Mukhtar H. 1997. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 89:1881-1886.
2. Bae SS, Perry DK, Oh YS, Choi JH, Galadari SH, Ghayur T, Ryu SH, Hannun YA, Suh PG. 2000. Proteolytic cleavage of phospholipase C-gamma1 during apoptosis in Molt-4 cells. FASEB J 14:1083-1092.
3. Bae J, Donigian JR, Hsueh AJ. 2003. Tankyrase 1 interacts with Mcl-1 proteins and inhibits their regulation of apoptosis. J Biol Chem 278: 5195-5204.
4. Bible KC, Kaufmann SH. 1996. Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861.
5. Cai D, Byth KF, Shapiro GI. 2006. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. Cancer Res 66:435-444.
6. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
7. Clare PM, Poorman RA, Kelley LC, Watenpaugh KD, Bannow CA, Leach KL. 2001. The cyclin-dependent kinases cdk2 and cdk5 act by a random, antic-ooperative kinetic mechanism. J Biol Chem 276:48292-48299.
8. Dai Y, Dent P, Grant S. 2002. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle 1:143-152.
9. Dancey J, Sausville EA. 2003. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2:296-313.
10. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. 1997. Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1-20.
11. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13:2905-2927.
12. Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, Dulchavsky SA, Gautam SC. 2007. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway. J Pharmacol Exp Ther 321:616-625.
13. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, Lovey A, Chen Y, Qian H, Hamid R, Xiang Q, Tovar C, Blain R, Nevins T, Higgins B, Luistro L, Kolinsky K, Felix B, Hussain S, Heimbrook D. 2006. In vitro and in vivo activity of R547: A potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 5:2644-2658.
14. Dobashi Y. 2005. Cell cycle regulation and its aberrations in human lung carcinoma. Pathol Int 55:95-105.
15. Dobashi Y, Shoji M, Jiang SX, Kobayashi M, Kawakubo Y, Kameya T. 1998. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol 153:963-972.
16. Donnerstag B, Ohlenschlager G, Cinatl J, Amrani M, Hofmann D, Flindt S, Treusch G, Trager L. 1996. Reduced glutathione and S-acetylglutathione as selective apoptosis-inducing agents in cancer therapy. Cancer Lett 110:63-70.
17. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, Kufe D. 1995. Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO J 14:6148-6156.
18. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, GonzalezBaron M. 2004. PI3K/Akt signaling pathway and cancer. Cancer Treat Rev 30:193-204.
19. Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM. 2008. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59-65.
20. Jang JH, Lee TJ, Yang ES, Min do S, Kim YH, Kim SH, Choi YH, Park JW, Choi KS, Kwon TK. 2010. Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated down-regulation of c-FLIPL and Mcl-1. Exp Cell Res 316:2194-2203.
21. Kitahara K, Yasui W, Kuniyasu H, Yokozaki H, Akama Y, Yunotani S, Hisatsugu T, Tahara E. 1995. Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 62:25-28.
22. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371:346-347.
23. Leach FS, Elledge SJ, Sherr CJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B. 1993. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 53:1986-1989.
24. Lee J, Choi H, Kim KH, Jeong S, Park JW, Baek CS, Lee SH. 2008. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett 18:2292-2295.
25. Leverrier Y, Thomas J, Mathieu AL, Low W, Blanquier B, Marvel J. 1999. Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ 6:290-296.
26. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, Byrd JC. 2009. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 27:6012-6018.
27. Liu X, Shi Y, Giranda VL, Luo Y. 2006. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol Cancer Ther 5:494-501.
28. Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P, Mancuso S. 1998. Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression. Int J Cancer 75:34-39.
29. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH. 1992. A family of human cdc2-related protein kinases. EMBO J 11:2909-2917.
30. Mgbonyebi OP, Russo J, Russo IH. 1999. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 59:1903-1910.
31. Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P. 2007. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther 6:3101-3112.
32. Morris DG, Bramwell VH, Turcotte R, Fiqueredo AT, Blackstein ME, Verma S, Matthews S, Eisenhauer EA. 2006. A phase II study of flavopiridol in patients with previously untreated advanced soft tissue sarcoma. Sarcoma 2006: 64374.
33. Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L, Zhang N, Leal J, Bush TL, Santora V, Askew B, Tasker A, Radinsky R, Kendall R, Coats S. 2006. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 66:4299-44308.
34. Pepper C, Thomas A, Fegan C, Hoy T, Bentley P. 2003. Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma 44:337-342.
35. Sausville EA. 2002. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8:S32-S37.
36. Schimmer AD, Dalili S, Batey RA, Riedl SJ. 2006. Targeting XIAP for the treatment of malignancy. Cell Death Differ 13:179-188.
37. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD, Courtney R, O'Dwyer PJ. 2011. Phase I study of PD0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:1862-1868.
38. Shankar S, Ganapathy S, Srivastava RK. 2008. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res 14:6855-6866.
39. Shi RX, Ong CN, Shen HM. 2005. Protein kinase C inhibition and x-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res 65:7815-7823.
40. Shin HC, Song DW, Baek WK, Lee SR, Kwon TK, Lee J, Park SH, Jang BC, Park JW. 2009. Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy 55:353-362.
41. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. 2003. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res 63:1822-1833.